VIP Dosage, Reconstitution & Mixing Trends

Explore vip calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized vip calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What VIP Is

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide most often sourced for respiratory, anti-inflammatory, and autonomic research. Its synthetic form, aviptadil, has been studied for pulmonary hypertension and COVID-19 respiratory failure. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

VIP binds two G-protein-coupled receptors (VPAC1 and VPAC2) widely expressed in vascular smooth muscle, alveolar type II pneumocytes, immune cells, and the CNS. VPAC2 activation in alveolar type II cells is thought to up-regulate surfactant production and reduce pro-inflammatory cytokine release, the rationale that motivated the aviptadil COVID-19 ARDS program.[2]

Inhaled aviptadil was evaluated in sarcoidosis (Prasse et al., Eur Respir J 2010) with positive bronchoalveolar-lavage cytokine effects but no consistent functional improvement.[3] The NIH-sponsored ACTIV-3b ARDS COVID-19 trial (TESICO) of intravenous aviptadil did not meet its primary endpoint (Wright et al., Lancet Respir Med 2023).[4] Earlier work in erectile dysfunction (Invicorp, fixed combination with phentolamine) is approved in some European markets.

Not FDA-approved as a single agent. Aviptadil (synthetic VIP) was studied in Phase 3 COVID-19 ARDS trials without meeting primary endpoints. Invicorp (aviptadil + phentolamine) is approved for erectile dysfunction in selected European markets. Research-grade material elsewhere.

VIP Research Sources

VIP Dosing Context

VIP has a reported half-life of ~1–2 min. The pharmacokinetic reference models an interval of multiple times daily (often nebulized/intranasal); this is not a measured community cadence or a dosing recommendation. Vasoactive intestinal peptide is degraded within a couple of minutes in the bloodstream, so there is no buildup at all — it is dosed frequently and acts only during brief exposure. Pharmacokinetic source: VIP pharmacology literature (rapid plasma degradation). It is catalogued under Memory Peptides on WPA.

VIP Community Calculator Data

177 VIP reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

VIP Research Background and Calculator Data

VIP — Vasoactive Intestinal Peptide — is a 28-amino acid neuropeptide first isolated from porcine duodenal extracts by Said and Mutt in 1970, and it acts through the VPAC1 and VPAC2 G-protein-coupled receptors as a broad immunomodulator, vasodilator, and bronchodilator. The published clinical record for VIP as a therapeutic spans several distinct programs: aviptadil — the synthetic VIP formulation developed by Mondo Biotech and later by NeuroRx and Relief Therapeutics — was advanced into pulmonary arterial hypertension and acute respiratory distress syndrome trials, and was the subject of a high-profile but ultimately negative COVID-19 ARDS Phase 2/3 program read out in 2021-2022. Inhaled aviptadil has also been studied in sarcoidosis and idiopathic pulmonary fibrosis at small clinical scales. None of these programs has produced a broadly-marketed VIP product, and the molecule remains research-only in most jurisdictions.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.